FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer October 15, 2025
Libtayo® (cemiplimab-rwlc) Approved in US for Adjuvant Treatment of CSCC with a High Risk of Recurrence After Surgery and Radiation October 15, 2025
Xintela’s oncology subsidiary, Targinta AB, and MSK’s Therapeutics Accelerator to develop integrin α10β1 antibody therapeutic in patients with aggressive sarcoma October 15, 2025
Tessera Therapeutics Awarded up to $41.3M from ARPA-H to Advance In Vivo CAR-T Therapies October 15, 2025
AstraZeneca announces agreement with US Government to lower the cost of medicines for American patients October 15, 2025
Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics October 15, 2025
Tempus Selected by HHS Agency to Provide Services for Precision Cancer Therapy Program October 15, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors October 15, 2025
Kincell Bio announces collaboration to advance Moonlight Bio’s lead cell therapy candidate to clinical study October 15, 2025
Enrollment in cohorts 1 & 2 of GTB-3650 Ph 1 Trial in Patients with R/R CD33 Expressing Heme Malignancies Completed October 15, 2025
Initial clinical data on the combination of AB8939 + venetoclax in the first three patients with R/R AML announced October 15, 2025
FAILED TRIAL: Zolbetuximab Ph 2 GLEAM Trial Did Not Meet Primary Endpoint of OS in Patients with Metastatic Pancreatic Cancer October 15, 2025
OPTIMIZE-1 biomarker analysis published in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer October 15, 2025
ONO-4578, Opdivo and Chemo combo Met the Primary Endpoint in Ph 2 Trial in Patients with 1L HER2-neg recurrent Gastric Cancer October 15, 2025
AlphaMedix™ (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in Ph 2 study in patients with GEP-NETs October 15, 2025
Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs October 15, 2025
Statistically Significant Final 2-Yr OS Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent Pulmonary Metastatic Osteosarcoma Announced October 15, 2025
HREC approves initiation of FIH Ph 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement October 15, 2025
Positive feedback from MHRA provides alignment on the preclinical, manufacturing, clinical & regulatory pathway for ZI-MA4-1 and supports planned CTA submission October 15, 2025
Ficerafusp Alfa Granted Breakthrough Therapy Designation by US FDA for 1L HPV-Negative R/M HNSCC October 15, 2025
FDA Fast Track Designation to WTX-124 for locally advanced or metastatic cutaneous melanoma after SOC immunotherapy October 15, 2025
FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma October 15, 2025
